Ticker brief
HROW HARROW INC
Consumer, Non-cyclical · Pharmaceuticals
last close
$37.27
1 day
-3.3%
14 days
-6.9%
mkt cap
$1.6B
signals 14d
11
authors 14d
6
crowd 14d
+0.5σ
Options inteloptions-surface reads · latest available day per source
| metric | reading | context |
|---|---|---|
| IV — ATM 30d | 60% mid · 25 pctile own 1y | IV/HV 1.02× (as of 2026-08-21) |
| Skew — 25Δ RR 30d | -0.097 20 pctile own 1y | puts bid vs calls (downside bid) |
| Net dealer OI (NDOI) | +4.84 elevated | 5-session Δ +0.64 (as of 2026-06-10) |
| OI alarm | quiet | last alarm 2025-10-30 (z=3.0) |
Sentiment — last 14 days
daily mean sentiment, 2026-08-17 → 2026-08-26 · now +0.10 (−1 bearish … +1 bullish)
Who spoke6
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @semodough | C | -3.01 | 4 | +0.28 |
| @TheRayMyers | B | -1.96 | 3 | +0.30 |
| @Biomaven | A | +1.79 | 1 | +0.40 |
| @ThePupOfWallSt | C | -0.47 | 1 | +0.65 |
| @LogicalThesis | A | +2.21 | 1 | +0.30 |
| @JonahLupton | A | -0.30 | 1 | +0.85 |
Recent signals11of 11 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-08-26 | @semodough | +0.40 | B. Riley rates HROW Buy at $60 while reporting BLCO's dry-eye Phase 2 primary-endpoint miss. | -5.2% | tweet ↗ |
| 2026-08-26 | @semodough | -0.20 | Long-term holder expresses frustration and demands management execution and conservative promises. | -5.2% | tweet ↗ |
| 2026-08-25 | @semodough | +0.50 | Calls HROW's MELT platform one of the better upside opportunities available. | -9.8% | tweet ↗ |
| 2026-08-25 | @JonahLupton | +0.85 | Discloses a fund long backed by a multi-year revenue, margin, EBITDA, and valuation thesis. | -9.8% | tweet ↗ |
| 2026-08-22 | @LogicalThesis | +0.30 | Suggests investors who like HROW may also find DERM attractive. | -9.0% | tweet ↗ |
| 2026-08-20 | @ThePupOfWallSt | +0.65 | Calls the HROW chart setup explosive. | -11.4% | tweet ↗ |
| 2026-08-20 | @TheRayMyers | +0.40 | Lake Street raises HROW's price target to $60, implying 42% upside over 12 months. | -11.4% | tweet ↗ |
| 2026-08-20 | @TheRayMyers | +0.50 | HROW trial showed IHEEZO reduced discomfort by about 58%, supporting its adoption case | -11.4% | tweet ↗ |
| 2026-08-19 | @TheRayMyers | +0.00 | Promotes a detailed HROW business, pipeline and valuation analysis without a stated stance. | -10.5% | tweet ↗ |
| 2026-08-18 | @Biomaven | +0.40 | Highlights insurance coverage as an advantage for HROW's Vevye versus dry-eye procedures. | -5.7% | tweet ↗ |
| 2026-08-17 | @semodough | +0.40 | B. Riley sets a $60 HROW target, citing de-risked guidance, demand growth and operating leverage. | -5.6% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.